Pulmonary function studies in patients with tropical eosinophilia have shown that during the early stages of the disease there is mild to moderate obstruction to the airways and that as the disease progresses there is, in addition, a restrictive ventilatory defect (Nesarajah, 1972) . Diethylcarbamazine is the specific drug used in the treatment of patients suffering from this disease. Although there are several reports of the clinical improvement observed in such patients after treatment (Chaudhuri, 1956;  Danaraj, 1958; Misra et al., 1959; Edirisinghe and Weerasinghe, 1963; Narang and Jain, 1966) , objective assessment of such improvement is not equally well documented (Udwadia, 1967; Azad Khan et al., 1970) . The present study was therefore undertaken to assess pulmonary function before and after treatment with diethylcarbamazine in patients with tropical eosinophilia in Sri Lanka.
MATERIAL AND METHODS
A group of 19 patients, 18 males and one female, was studied. All patients gave the typical clinical history, had circulating eosinophil counts of over 2000/,ul of blood, positive filaria complement fixation tests, and elevated erythrocyte sedimentation rates, and showed a clinical and haematological response to diethylcarbamazine, thereby satisfying the criteria recommended by Donohugh (1963) for the diagnosis of tropical eosinophilia. Before their entry into the study, none of these patients had been receiving any specific therapy for tropical eosinophilia. The duration of symptoms was less than one month in 10 patients and from one to five months in the remaining nine. The patients were accordingly divided into two groups-group A, with symptoms of less than one month's duration, and group B, with symptoms of more than one month's duration.
The lung volumes and expiratory flow rates were measured using a Godart Pulmonet, Aika spirometer, and a Wright peak flow meter, as described in a previous paper (Nesarajah, 1972) . The patients were treated with diethylcarbamazine, 250 mg three times a day for 7 days, and the above measurements were repeated after the course of treatment was over. The erythrocyte sedimentation rate and the absolute eosinophil count were measured, and the filaria complement fixation test was also carried out both before and after treatment in all patients.
In 17 of the patients the measurements were repeated within two weeks to six months after completion of the course of treatment, in one subject after eight months, and in one other subject 16 Table. The mean values for the VC, FEV, and PEFR for both groups of patients before treatment were found to be significantly lower than for the normal subjects, while the mean values for TLC for either group was not different from that for the normal subjects. Following treatment, in both groups of patients there was a significant increase (P<0-01) in the VC, FVC, FEV,, and PEFR. The posttreatment VC for both groups of patients and the FEVY for group A patients reached normal levels whereas the FEV, for group B patients and the PEFR for both groups were still significantly lower than for the normal subjects.
The (Danaraj, 1958; Ganatra, Sheth, and Lewis, 1958; Shanker, Bhargava, and Shrivastava, 1960; Islam, 1964) . The cure rate with diethylcarbamazine therapy, as commonly gauged by amelioration of symptoms, disappearance of the lung signs, a clearing of the radiological picture, a return of the erythrocyte sedimentation rate to normal, and a decrease in the eosinGphil count, ranges from about 80% to 100% in various series (Ganatra and Lewis, 1955; Danaraj, 1958; Ganatra et al., 1958; Shanker et al., 1960; Narang and Jain 1966; Azad Khan et al., 1970) . Udwadia (1967) observed a poor response to treatment (and so a low cure rate) in patients with a long history and with fibrosis of the lung, and there is now evidence that some of the cases which do not respond to treatment may have a non-filarial aetiology (Joshi, Udwadia, and Gadgil, 1969 Although Danaraj (1958) , using different daily dosage schedules for treatment, observed that the clinical respons'e was better with daily doses of 18 and 30 mg/kg body weight than with the smaller dose, several workers both in India (Patwari, 1958; Viswanathan and Krishnamurthil, 1958; Baker, Rajan, and Devadatta, 1959) and in Ceylon (Edirisinghe and Weerasinghe, 1963; Attygalle, 1970) have found that diethylcarbamazine in as small a daily dose as S to 8 mg/kg body weight given for about a week to 10 days is effective. Shanker and Gaur (1971) used different dosage schedules and observed that the cure rate was dependent upon the total quantity of drug administered irre-spective of the period of therapy. These findings confirm the earlier observations of G-anatra and Lewis (1955) . Shanker and Gaur (1971) and Danaraj (1958) have also observed that with higher daily doses the clinical response was quicker than with lower daily doses. In the present series the total amount of drug administered was about 5 g in a daily dosage of about 12 mg/kg body weight.
Although clinical improvement with diethylcarbamazine therapy usually starts in two to four days after the beginning of treatment and most patients are completely free of symptoms by the end of the second week, the haematological response takes slightly longer (Danaraj, 1958; Narang and Jamn, 1966; Crofton and Douglas, 1969) . From the present study it seems that the time taken for pulmonary function to return to normal, if it does, is much longer than for both the clinical and the haematological response.
Even though the VC had returned to normal levels in both groups, the improvement in the airways obstruction with treatment, though significant, was still incomplete, particularly in the group B patients. These observations are consistent with the findings of Udwadia and Joshi (1964) 
